market-trends is the sole category represented across all 1 tracked stories. Activin E is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Kate Rausch appears in 1 tracked Healthcare story from August 4, 2026. The tracked stories average 2 original sources each.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Kate Rausch
market-trends is the sole category represented across all 1 tracked stories. Activin E is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Kate Rausch appears in 1 tracked Healthcare story from August 4, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Kate Rausch. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
